MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pemetrexed (Alimta)

Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

Japanese Journal of Clinical Oncology 2019 July 9 [Link] Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare cancer for which no standard systemic chemotherapy has been established. While cisplatin plus […]

Comments Off on Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

Clinical Cancer Research 2019 July 1 [Link] Hassan R, Alley E, Kindler H, Antonia SJ, Jahan TM, Honarmand S, Nair N, Whiting C, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy A, Jaffee EM, Coussens LM, Brockstedt DG Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer […]

Comments Off on Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

Anticancer Research 2019 July [Link] Gerogianni I, Pitaraki E, Jagirdar RM, Kouliou O, Giannakou L, Giannopoulos S, Papazoglou E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG Abstract BACKGROUND/AIM: Malignant pleural mesothelioma (MPM) is a therapy-resistant neoplasm of the pleura. Standard chemotherapy consists of a combination of cisplatin (CPDD) and pemetrexed (PEM). The aim of this study […]

Comments Off on 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Clinical Cancer Research 2019 June 7 [Link] Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V Abstract PURPOSE: The IFCT-GFPC-0701 MAPS Phase III trial […]

Comments Off on Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.

International Journal of Cancer 2019 May 20 [Link] Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C Abstract Malignant pleural mesothelioma (MPM) is a tumor with high chemoresistance […]

Comments Off on Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

The Lancet. Respiratory Medicine. 2019 May 15 [Link] Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim […]

Comments Off on Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

Investigational New Drugs 2019 May 7 [Link] van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J Abstract Background Fibroblast […]

Comments Off on A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.

Cureus 2019 February 20 [Link] Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive disease, with few, if any, curative interventions. While there is growing interest in using immunotherapy and immuno-gene therapy to treat MPM, very limited data currently exist for combining these modalities with […]

Comments Off on First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.

AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression.

Molecular Oncology 2019 April 29 [Link] Qin Y, Sekine I, Hanazono M, Morinaga T, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Yamaguchi N, Tagawa M Abstract Pemetrexed (PEM) inhibits DNA and RNA synthesis and is currently one of the first-line agents for mesothelioma. PEM suppresses the activities of several enzymes involved in purine and […]

Comments Off on AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

Current Treatment Options in Oncology 2019 February 21 [Link] Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D’Argento E Abstract Unresectable or relapsed malignant pleural mesothelioma (MPM) has dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, […]

Comments Off on Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”